Matched-pair analysis of mCRPC patients receiving <sup>177</sup>Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.

EJNMMI Res · 2024 · PMC11473467 · PMID 39402311

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Results from this analysis showed a trend towards better response rates and longer survival times with the higher dose and shorter intervals, without compromising safety.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.